• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

治疗方案可能会影响肝硬化的肠道微生物组衍生特征。

Treatment regimens may compromise gut-microbiome-derived signatures for liver cirrhosis.

机构信息

Key Laboratory of Molecular Biophysics of the Ministry of Education, Hubei Key Laboratory of Bioinformatics and Molecular Imaging, Center for Artificial Intelligence Biology, Department of Bioinformatics and Systems Biology, College of Life Science and Technology, Huazhong University of Science and Technology, 430074 Wuhan, Hubei, China.

Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, 200433 Shanghai, China; Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence, Ministry of Education, Shanghai 200433, China; Research Institute of Intelligent Complex System, Fudan University, Shanghai 200433, China.

出版信息

Cell Metab. 2021 Mar 2;33(3):455-456. doi: 10.1016/j.cmet.2021.02.012.

DOI:10.1016/j.cmet.2021.02.012
PMID:33657385
Abstract

Many of the gut-microbiome-derived signatures for liver cirrhosis, especially the important ones, were likely under the influence of proton pump inhibitors (PPIs). Wu et al. suggest that drug usage is a confounding factor in metagenomics analysis that should be controlled for.

摘要

许多源自肠道微生物组的肝硬化特征,尤其是重要的那些,可能受到质子泵抑制剂(PPIs)的影响。Wu 等人建议,药物使用是宏基因组分析中的一个混杂因素,应该加以控制。

相似文献

1
Treatment regimens may compromise gut-microbiome-derived signatures for liver cirrhosis.治疗方案可能会影响肝硬化的肠道微生物组衍生特征。
Cell Metab. 2021 Mar 2;33(3):455-456. doi: 10.1016/j.cmet.2021.02.012.
2
Proton pump inhibitor use status does not modify the microbiome signature for cirrhosis.质子泵抑制剂的使用状况不会改变肝硬化的微生物组特征。
Cell Metab. 2021 Mar 2;33(3):457. doi: 10.1016/j.cmet.2021.02.013.
3
Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis.通过定量宏基因组学评估肝硬化患者肠道微生物群的改变:与慢加急性肝衰竭及预后的关系
Gastroenterology. 2021 Jan;160(1):206-218.e13. doi: 10.1053/j.gastro.2020.08.054. Epub 2020 Sep 14.
4
Changes in the Microbiome in Cirrhosis and Relationship to Complications: Hepatic Encephalopathy, Spontaneous Bacterial Peritonitis, and Sepsis.肝硬化患者微生物组的变化及其与并发症的关系:肝性脑病、自发性细菌性腹膜炎和脓毒症
Semin Liver Dis. 2016 Sep;36(4):327-330. doi: 10.1055/s-0036-1593881. Epub 2016 Dec 20.
5
A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease.非酒精性脂肪性肝病相关肝硬化的肠道微生物组特征。
Nat Commun. 2019 Mar 29;10(1):1406. doi: 10.1038/s41467-019-09455-9.
6
Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis.长期质子泵抑制剂治疗期间口腔化的生物标志物可预测肝硬化患者的生存率。
Sci Rep. 2019 Aug 19;9(1):12000. doi: 10.1038/s41598-019-48352-5.
7
Adjusting for age improves identification of gut microbiome alterations in multiple diseases.调整年龄可提高多种疾病中肠道微生物组改变的识别能力。
Elife. 2020 Mar 11;9:e50240. doi: 10.7554/eLife.50240.
8
The gut microbiome in atherosclerotic cardiovascular disease.动脉粥样硬化性心血管疾病中的肠道微生物群
Nat Commun. 2017 Oct 10;8(1):845. doi: 10.1038/s41467-017-00900-1.
9
Oral microbiome alterations of healthy volunteers with proton pump inhibitor.质子泵抑制剂对健康志愿者口腔微生物组的影响。
J Gastroenterol Hepatol. 2018 May;33(5):1059-1066. doi: 10.1111/jgh.14040. Epub 2018 Feb 14.
10
Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients.质子泵抑制剂或瑞巴派特使用对类风湿关节炎患者肠道微生物群的影响。
Rheumatology (Oxford). 2021 Feb 1;60(2):708-716. doi: 10.1093/rheumatology/keaa316.

引用本文的文献

1
Efficient Recovery of Complete Gut Viral Genomes by Combined Short- and Long-Read Sequencing.通过短读长读联合测序实现完整肠道病毒基因组的高效回收。
Adv Sci (Weinh). 2024 Apr;11(13):e2305818. doi: 10.1002/advs.202305818. Epub 2024 Jan 19.
2
Performance of Gut Microbiome as an Independent Diagnostic Tool for 20 Diseases: Cross-Cohort Validation of Machine-Learning Classifiers.肠道微生物组作为 20 种疾病独立诊断工具的性能:基于机器学习分类器的跨队列验证。
Gut Microbes. 2023 Jan-Dec;15(1):2205386. doi: 10.1080/19490976.2023.2205386.
3
Aryl Hydrocarbon Receptor (AhR) Activation by 2,3,7,8-Tetrachlorodibenzo--Dioxin (TCDD) Dose-Dependently Shifts the Gut Microbiome Consistent with the Progression of Non-Alcoholic Fatty Liver Disease.
2,3,7,8-四氯二苯并二恶英(TCDD)通过芳基烃受体(AhR)激活作用剂量依赖性地改变肠道微生物组,与非酒精性脂肪性肝病的进展一致。
Int J Mol Sci. 2021 Nov 18;22(22):12431. doi: 10.3390/ijms222212431.
4
GMrepo v2: a curated human gut microbiome database with special focus on disease markers and cross-dataset comparison.GMrepo v2:一个经过精心策划的人类肠道微生物数据库,特别关注疾病标志物和跨数据集比较。
Nucleic Acids Res. 2022 Jan 7;50(D1):D777-D784. doi: 10.1093/nar/gkab1019.
5
Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant Metastasis.非小细胞肺癌及其远处转移中人类肺部和肠道微生物组的改变。
Microbiol Spectr. 2021 Dec 22;9(3):e0080221. doi: 10.1128/Spectrum.00802-21. Epub 2021 Nov 17.
6
mBodyMap: a curated database for microbes across human body and their associations with health and diseases.mBodyMap:一个经过精心策划的人体微生物数据库,以及它们与健康和疾病的关联。
Nucleic Acids Res. 2022 Jan 7;50(D1):D808-D816. doi: 10.1093/nar/gkab973.